Amydis announces successful pre-IND meeting with FDA to develop retinal tracer for amyloid angiopathy diagnosis
January 11, 2021
Amydis announced the successful completion of a pre-investigational new drug (IND) meeting with the FDA for its candidate AMDX-2011P, a small-molecule retinal tracer that targets amyloid beta to diagnosis amyloid angiopathy.